1. Home
  2. TNGX vs BEAG Comparison

TNGX vs BEAG Comparison

Compare TNGX & BEAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • BEAG
  • Stock Information
  • Founded
  • TNGX 2014
  • BEAG 2021
  • Country
  • TNGX United States
  • BEAG United States
  • Employees
  • TNGX N/A
  • BEAG N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • BEAG
  • Sector
  • TNGX Health Care
  • BEAG
  • Exchange
  • TNGX Nasdaq
  • BEAG NYSE
  • Market Cap
  • TNGX 317.4M
  • BEAG 309.1M
  • IPO Year
  • TNGX N/A
  • BEAG 2024
  • Fundamental
  • Price
  • TNGX $1.95
  • BEAG $10.04
  • Analyst Decision
  • TNGX Strong Buy
  • BEAG
  • Analyst Count
  • TNGX 7
  • BEAG 0
  • Target Price
  • TNGX $12.33
  • BEAG N/A
  • AVG Volume (30 Days)
  • TNGX 817.7K
  • BEAG 6.4K
  • Earning Date
  • TNGX 05-07-2025
  • BEAG 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • BEAG N/A
  • EPS Growth
  • TNGX N/A
  • BEAG N/A
  • EPS
  • TNGX N/A
  • BEAG 0.08
  • Revenue
  • TNGX $42,069,000.00
  • BEAG N/A
  • Revenue This Year
  • TNGX N/A
  • BEAG N/A
  • Revenue Next Year
  • TNGX N/A
  • BEAG N/A
  • P/E Ratio
  • TNGX N/A
  • BEAG $827.63
  • Revenue Growth
  • TNGX 15.17
  • BEAG N/A
  • 52 Week Low
  • TNGX $1.72
  • BEAG $10.00
  • 52 Week High
  • TNGX $12.02
  • BEAG $10.57
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 37.66
  • BEAG N/A
  • Support Level
  • TNGX $1.80
  • BEAG N/A
  • Resistance Level
  • TNGX $2.01
  • BEAG N/A
  • Average True Range (ATR)
  • TNGX 0.21
  • BEAG 0.00
  • MACD
  • TNGX 0.01
  • BEAG 0.00
  • Stochastic Oscillator
  • TNGX 31.94
  • BEAG 0.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About BEAG BOLD EAGLE ACQUISITION CORP

Bold Eagle Acquisition Corp is a blank check company.

Share on Social Networks: